Matrilysin is a matrix metalloproteinase expressed in the tumor cells of greater than 80% of intestinal adenomas. The majority of these intestinal tumors are associated with the accumulation of b-catenin, a component of the cadherin adhesion complex and, through its association with the T Cell Factor (Tcf) DNA binding proteins, a regulator in the Wnt signal transduction pathway. In murine intestinal tumors, matrilysin transcripts show striking overlap with the accumulation of b-catenin protein. The matrilysin promoter is upregulated as much as 12-fold by b-catenin in colon tumor cell lines in a manner inversely proportional to the endogenous levels of b-catenin/Tcf complex and is dependent upon a single optimal Tcf-4 recognition site. Coexpression of the Ecadherin cytoplasmic domain blocked this induction and reduced basal promoter activity in every colon cancer cell line tested. Inactivation of the Tcf binding site increased promoter activity and overexpression of the Tcf factor, LEF-1, signi®cantly downregulated matrilysin promoter activity, suggesting that b-catenin transactivates the matrilysin promoter by virtue of its ability to abrogate Tcf-mediated repression. Because genetic ablation of matrilysin decreases tumor formation in multiple intestinal neoplasia (Min) mice, we propose that regulation of matrilysin production by b-catenin accumulation is a contributing factor to intestinal tumorigenesis.
Introduction
Mutations in both alleles of the adenomatous polyposis coli (APC) gene which result in the production of truncated APC protein have been associated with greater than 70% of human intestinal adenomas (Kinzler and Vogelstein, 1996, for review) . Patients with familial adenomatous polyposis (FAP) carry a germline truncating mutation in an allele of APC and are predisposed to develop a multitude of colonic adenomas. Re-expression of APC in colon tumor cell lines inhibits tumor growth and leads to apoptosis, formalizing its classi®cation as a tumor suppressor (Groden et al., 1995; Morin et al., 1996) . As a tumor suppressor whose loss of function is associated with the earliest stages of intestinal tumorigenesis, Vogelstein and colleagues have labeled APC the`gatekeeper' of the process , suggesting that only after APC function has been eliminated may intestinal tumorigenesis proceed through a multistep progression during which other mutations are acquired.
The mechanism of the APC gatekeeper function has been largely attributed to the role it plays in targeting b-catenin for degradation. Originally identi®ed as a protein that interacts with the cytoplasmic domain of E-cadherin, b-catenin has been shown to be important for epithelial cell/cell contact (Aberle et al., 1996) . In intestinal tumors and colon tumor cell lines with mutant APC, b-catenin protein accumulates throughout the cell and re-expression of wild type APC in these cell lines reduces b-catenin levels dramatically (Munemitsu et al., 1995) . The hypothesis that b-catenin accumulation is the critical step in intestinal tumorigenesis is further bolstered by the ®nding that a majority of colon tumors and colon tumor cell lines with no APC mutations instead have mutations in the b-catenin gene from which a stable form of the protein is produced Sparks et al., 1998) .
The mechanism by which b-catenin stabilization may lead to intestinal tumorigenesis is unknown, but recent evidence suggests that b-catenin may act as a transcriptional cofactor through its association with members of a family of DNA binding proteins known as the T cell factors (Tcf). b-catenin expression enhances the activity of arti®cial promoters consisting of reiterative Tcf binding sites and APC expression represses this promoter activity . Aside from these arti®cial promoters, the majority of targets for b-catenin transactivation have been limited to developmental systems (Brannon et al., 1997; McKendry et al., 1997) , with c-myc being only recently identi®ed as a target in human colon cancer cell lines (He et al., 1998) .
Matrilysin EC#3.4.24.23 ) is a matrix metalloproteinase expressed in the malignant epithelium of approximately 90% of human colonic adenocarcinomas and in a majority of human colon tumor cell lines . Unlike other matrix metalloproteinases whose expression correlates with the invasive and metastatic stages of tumor progression, matrilysin is also expressed in precancerous polyps suggesting a signi®cance prior to the onset of the invasive phenotype. Strikingly, matrilysin mRNA expression is found in over 90% of intestinal adenomas resulting from germline mutations in the APC gene in both human (Takeuchi et al., 1998) and mouse (Wilson et al., 1997) . Metalloproteinases, and matrilysin in particular, are now recognized as contributing to tumor establishment and growth (Chambers and Matrisian, 1997) . Experiments altering levels of matrilysin expression in human colon tumor cell lines have shown that matrilysin enhances tumor formation following orthotopic injection into nude mice . Furthermore, genetic ablation of matrilysin in the multiple intestinal neoplasia (Min) mouse model system reduces adenoma formation by 60% (Wilson et al., 1997) . The expression pattern of matrilysin and its contribution to tumor formation suggest that matrilysin is a relevant target gene for signal transduction pathways known to be active in intestinal adenomas, such as b-catenin/Tcf transactivation.
Results

Expression of the endogenous matrilysin gene correlates with b-catenin accumulation
To address a possible connection between b-catenin accumulation and matrilysin expression, we examined adenomas in the C57/B16/Min + mouse as well as azoxymethane (AOM)-induced colon adenocarcinomas in C57/B16 mice for a correlation of b-catenin protein and matrilysin transcripts (Figure 1 and data not shown). As reported previously, 90% of Min tumors expressed matrilysin (Wilson et al., 1997) and 100% (14/14) of AOM-induced tumors examined in this study produced both matrilysin transcripts and protein. In both tumor types, matrilysin transcripts were detectable only in regions demonstrating elevated levels of b-catenin protein (Figure 1) . On rare occasions, b-catenin accumulation was observed in some tumor cells where matrilysin transcripts were not evident. However, longer exposures of nearby sections clearly showed matrilysin transcripts in these regions as well. Nonetheless, these dierent levels of endogenous matrilysin gene expression suggest that there is tumor heterogeneity with respect to other signals that can in¯uence absolute levels of steady state matrilysin transcripts. As expected, neither bcatenin nor matrilysin were found at high levels in the surrounding normal tissue, with the exception of the previously reported matrilysin expression in the Paneth cells of the small intestine (Wilson et al., 1995) . Thus it appeared that accumulation of b- 
b-catenin interacts with and regulates the matrilysin promoter
To explore the possibility that matrilysin is a direct target of b-catenin transactivation, the mouse matrilysin promoter was cloned and sequenced ( Figure 2a) . In addition to a single canonical AP-1 site and consensus Ets binding sites, both of which are common to most matrix metalloproteinase promoters (Crawford and Matrisian, 1996) , the matrilysin promoter contained a single optimal Tcf-4 binding site eight basepairs downstream of the transcription start site (+8-Tcf).
Electrophoretic mobility shift assays (EMSAs) indicated that the matrilysin +8-Tcf site bound two prominent nuclear protein complexes similar to those bound by the optimal Tcf-4 site . The faster migrating complex has been identi®ed as Tcf binding while the slower migrating complex is a product of the b-catenin/Tcf bipartite complex. The binding of these complexes was reduced when a two basepair mutation previously shown to eliminate Tcf binding was introduced into the oligonucleotide probe ( Figure 3a) . We con®rmed that b-catenin from colon tumor cell nuclear extracts interacted with the +8-Tcf site in vitro by EMSA with a b-catenin monoclonal antibody that interfered with the b-catenin interaction ( Figure 3b ). Using nuclear extracts prepared from a variety of colon tumor cell lines revealed that the relative levels of the b-catenin/Tcf complex varied ( Figure 3b ). SW480 and SW620 cells had relatively high levels of the b-catenin-containing complex, while HT29 had moderate and HCT116 had low levels. These data were consistent with a previous observation that SW480 cells have a large pool and HCT116 cells a relatively small amount of b-catenin unassociated with E-cadherin (Stewart and Nelson, 1997) . Because the apparently low levels of b-catenin/Tcf in some of the cell lines could be due to the lack of either b-catenin or Tcf, we performed an EMSA with HCT116 nuclear extracts and supplemented the extracts with puri®ed bcatenin. The addition of exogenous b-catenin increased the prominence of the b-catenin/Tcf complex, indicating the presence of excess Tcf monomer (Figure 3c ). The identity of the b-catenin/Tcf complex was con®rmed by the addition of a dierent anti-b-catenin monoclonal antibody that did not interfere with bcatenin/Tcf interaction, but instead supershifted the bcatenin/Tcf complex. Similar results were obtained with HT29 nuclear extracts (data not shown). Thus, the variable levels of b-catenin/Tcf able to bind to the matrilysin +8-Tcf site were not due to the lack of Tcf factors, but were more likely due to variable amounts of nuclear b-catenin. The diering levels of b-catenin/ Tcf in these cell lines provided a useful system for determining a functional role for b-catenin in the regulation of the matrilysin promoter.
To help determine the potential role of b-catenin in regulation of the matrilysin promoter, a 2.7 kb promoter fragment was cloned into a luciferase reporter construct (WTMAT-Luc) ( Figure 2b ). In HT29 and HCT116 cells, which have a moderate to low level of endogenous b-catenin/Tcf complex, cotransfection of WTMAT-Luc with an expression vector encoding an inherently stable truncated form of human b-catenin (DN89b-catenin, Munemitsu et al., 1996) resulted in a sixfold and 12.5-fold induction of matrilysin promoter activity, respectively ( Figure 4a ). In SW480 and SW620 cells, which have high levels of endogenous b-catenin/Tcf, expression of DN89b-catenin did not signi®cantly aect matrilysin promoter activity ( Figure 4a ). To determine if the b-catenin induction of the promoter was dependent upon the +8-Tcf site, we introduced the mutation shown to disrupt Tcf binding into the reporter construct to generate mTcfMAT-luc ( Figure 2b ). The induction of promoter activity by b-catenin was greatly reduced in the mutant construct, indicating that this site is a site of b-catenin action.
It has been shown previously that E-cadherin acts as an inhibitor of the Wnt signal transduction pathway (Fagotto et al., 1996) . We hypothesized that this might be due to the overlapping binding sites of E-cadherin and Tcf factors (Behrens et al., 1996) , making the cytoplasmic tail of E-cadherin a potentially powerful repressor of b-catenin transactivation. To test this repressive activity, an expression vector containing the E-cadherin cytoplasmic tail with a translation start codon provided by a myc epitope tag was constructed. Cotransfection of this E-cadCyto expression vector Represented are WTMAT-Luc, which includes approximately 2.7 kb of the wild type matrilysin promoter sequence cloned upstream of the ®re¯y luciferase reporter gene, and mTCFMATLuc which is identical to WTMAT-Luc except for the indicated two base pair mutation at the putative Tcf binding site with the matrilysin promoter reduced promoter activity to essentially background levels in the HCT116 cell line and completely eliminated the promoter-inducing activity of cotransfected DN89b-catenin as compared to cotransfection with empty expression vector (Figure 4b ). Basal matrilysin promoter activity was repressed by E-cadCyto in every colon tumor cell line tested as compared to cotransfection with an expression vector containing an E-cadherin cytoplasmic domain with the b-catenin interaction region deleted (E-cadCytoD) (Figure 4c ). Matrilysin promoter activity in the SW480 and SW620 1 2 3 4 5 myc Supershift by addition of a mouse monoclonal antibody (Clone 14) con®rmed the identity of the b-catenin-containing complex. An equivalent amount of anti-myc monoclonal antibody was used as a control cells was repressed by E-cadCyto to a greater degree than it was in HT29 and HCT116 cells. This repressive activity of E-cadCyto was eective only on the wild type matrilysin promoter but not eective on the mTCFMAT-luc construct in the SW480 cells ( Figure  4d ). Therefore, in addition to the observation that exogenous b-catenin could enhance matrilysin promoter activity, our data suggested that endogenous bcatenin was essential for maintenance of basal matrilysin promoter activity in each cell line examined, including those with relatively low levels of bcatenin/Tcf, in a +8-Tcf site dependent manner.
Tcf is a repressor of matrilysin promoter activity It became evident in the course of these studies that the nature of the b-catenin eect on the matrilysin promoter may not be due to simple activation of promoter activity. Although the +8-Tcf site was required for maximal DN89b-catenin induction and E-cadCyto repression of the matrilysin promoter, constitutive promoter activity from mTCFMAT-Luc was 3 ± 5-fold higher than that of WTMAT-Luc in HT29 and HCT116 cells (Figure 5a ). The higher activity of mTCFMAT-Luc in the two cell lines most responsive to b-catenin cotransfection and with relatively low levels of endogenous b-catenin/Tcf complex was consistent with an observation made with the Xenopus siamois promoter, that is that Tcf in the absence of b-catenin acts as a transcriptional repressor (Brannon et al., 1997) . To directly address the repressive activity of a Tcf factor on the matrilysin promoter, an expression vector encoding the Tcf family member LEF-1 was cotransfected with the promoter into cells with high (SW480) or with low (HCT116) levels of b-catenin/Tcf. LEF-1 cotransfection reduced matrilysin promoter activity signi®cantly in SW480 cells, but not in HCT116 cells (Figure 5b) . Although b-catenin/Tcf complex acts as a transcriptional activator on the siamois promoter (Brannon et al., 1997) , it is important to note that mutation of the matrilysin +8-Tcf site did not reduce transcriptional activity in cells with high levels of b-catenin/Tcf complex, such as SW480 and SW620 cells ( Figure  4a ). Thus, in these cells, the matrilysin promoter with a non-functional Tcf site showed equivalent activity to a wild type promoter binding high levels of b-catenin/ Tcf. These data are consistent with b-catenin relieving transcriptional repression by Tcf, but not acting directly as a transcriptional activator at the +8-Tcf site.
Discussion
Matrilysin is expressed in the benign epithelium of approximately 90% of intestinal adenomas that arise as a result of germline mutations in the APC gene in both mouse and man (Wilson et al., 1997; Takeuchi et al., 1998) . Since the formation of adenomas is associated with the loss of the normal APC allele, this pattern of expression is consistent with matrilysin being a downstream target of the signal transduction pathway(s) upregulated by the loss of APC function. The positive correlation between elevated b-catenin protein levels and matrilysin transcripts strengthened this possibility. However, the correlation observed in colon tumors induced by AOM is a more meaningful test of a direct relationship since tumors that arise through random mutagenesis potentially result from mutations independent of APC/b-catenin. In this study, the AOM tumors showed a higher degree of heterogeneity with respect to b-catenin staining than did the Min tumors, but all AOM tumors had at least some regions with elevated b-catenin immunoreactivity. Signi®cantly, we never found matrilysin expression in tumor cells that did not also show a high level of b-catenin, suggesting that the correlation of endogenous matrilysin gene expression and b-catenin protein accumulation was not merely the passive coincidence of two unrelated tumorspeci®c events.
In addition to the in vivo overlap of b-catenin and matrilysin, we have shown that the matrilysin promoter contains an optimal Tcf-4 site located eight base pairs downstream of the transcriptional start site that interacts with b-catenin in vitro. Further, the matrilysin promoter is upregulated by b-catenin and can be downregulated by the wild type cytoplasmic domain of E-cadherin with both induction and repression being dependent upon the wild type Tcf-4 site. b-catenin had no in¯uence on promoter activity in cell lines with the highest amounts of b-catenin/Tcf, suggesting that these cell systems were saturated with the bipartite complex enough to fully activate the amount of promoter/reporter construct introduced into the cells. Conversely, cells like the HCT116 cells with little b-catenin/Tcf, but with signi®cant amounts of free Tcf, were very responsive to b-catenin overexpression.
It should be noted that mutation of the +8-Tcf site was not sucient for complete abrogation of b-catenin mediated induction. As yet, we have identi®ed no additional canonical Tcf sites in the promoter, though there are multiple elements similar in sequence that remain uncharacterized. Another possible mechanism of the continued induction of the mutant promoter could be that other b-catenin targets feed back on the matrilysin promoter. Cotransfection with c-myc, the only mammalian b-catenin target gene reported at this time (He et al., 1998) , has no eect on the matrilysin promoter (data not shown). Although other b-catenin dependent regulatory mechanisms may contribute to matrilysin promoter activity, the considerable loss of bcatenin responsiveness by mutation of the +8-Tcf site suggests that this sequence is a major site of b-catenin regulation.
Unexpectedly, the promoter with a mutated Tcf-4 site was more active in cells with moderate to low levels of b-catenin/Tcf complex indicating that in these cells, the Tcf-4 site is the binding site for a transcriptional repressor. Based upon the hypothesis that this repressor was a Tcf family member without associated b-catenin, we have shown that LEF-1 can repress the promoter. In contrast to induction by bcatenin, this repression was more eective in cells with high levels of b-catenin/Tcf than in cells where most of the Tcf protein was not associated with b-catenin. Thus, Tcf family members are more than inactive bystanders as has been suggested in studies using arti®cial promoters. Our observations support the functional observation made with the Xenopus siamois promoter and human myc promoters: that Tcf family members act as transcriptional repressors until bcatenin levels accumulate to a point where sucient bcatenin/Tcf heterodimer forms to relieve this repression (Brannon et al., 1997; He et al., 1998) . Unlike the siamois promoter however, we ®nd no evidence that b-catenin has a positive transcriptional role on the matrilysin promoter beyond relief of Tcf-mediated repression.
Regulation of the matrilysin promoter at the +8-Tcf site could result from torsional stress on the DNA created by Tcf (Giese et al., 1992; Love et al., 1995) and subsequent relief of this stress by b-catenin binding to Tcf (Behrens et al., 1996) . Such a mechanism in the general vicinity of the transcriptional start site would seem an ideal mechanism of repression. However, the human matrilysin promoter shows a similar derepression of promoter activity when one of its two Tcf sites is mutated despite being located more than 100 bp upstream of transcriptional initiation (unpublished data). Also, Tcf sites in the siamois and myc promoters are not located particularly close to the transcriptional initiation site, but can act as sites of transcriptional repression (Brannon et al., 1997; He et al., 1998) . Therefore, while Tcf repression of the mouse matrilysin promoter may indeed result from impeded progress of the general transcriptional machinery, a more direct mechanism of Tcf-mediated repression seems more likely. Support for such a mechanism emerged while this manuscript was under consideration with several groups attributing the repressive activity of Tcf to an interaction with the transcriptional co-repressor Groucho (Levanon et al., 1998; Cavallo et al., 1998; .
Our data indicate that matrilysin promoter activity is responsive to alterations in b-catenin/Tcf levels in tumor cells lines in which b-catenin is stabilized as a result of either mutant APC (SW480, SW620 and HT29) (Groden et al., 1991; Ilyas et al., 1997; Morin et al., 1996) or mutant b-catenin (HCT116) . Though all of these cell lines make endogenous matrilysin, the levels of expression vary widely, consistent with our identi®cation of the rare tumor region with abundant b-catenin without correspondingly high levels of matrilysin. The lack of an absolute correlation between b-catenin and matrilysin overexpression emphasizes the role of bcatenin as a signal that relieves repression and suggests the contribution of additional signals. Indeed, basal matrilysin promoter activity is completely dependent upon the oncogene-and growth factorresponsive AP-1 site (unpublished data). In cells with low levels of matrilysin, endogenous matrilysin gene expression and promoter activity can be greatly enhanced by growth factors and cytokines (Gaire et al., 1994) , further emphasizing the importance of additional factors. However, sequestration of bcatenin by E-cadCyto abrogated growth factorinduced promoter activity (data not shown). From this we hypothesize that b-catenin/Tcf complex bound to the +8-Tcf site creates a permissive state that allows secondary signals to modulate the ultimate levels of matrilysin expression.
The regulation of a secreted ECM-degrading proteinase by b-catenin accumulation has implications for colon cancer and tumorigenesis in general. Many elegant studies have shown that alterations in the extracellular environment can have a profound in¯uence on the behavior of cells. Extracellular matrix can essentially reverse the tumor phenotype of carcinoma cells in culture (Weaver et al., 1997) while expression of matrix metalloproteinases can induce tumor phenotypes in well-dierentiated cells (Lochter et al., 1997) . In most carcinomas, MMPs are expressed in stromal cells and many have been shown to be regulated by interaction with ECM through integrins (Pilcher et al., 1997; Damsky et al., 1997) . In contrast, matrilysin expression is found at high levels in well-dierentiated epithelial cells (Wilson and Matrisian, 1998) and has been shown to be tightly regulated by E-cadherin mediated cell/cell contact (Borchers et al., 1997) . Thus, the expression pattern of these enzymes are at least partly controlled by the particular extracellular environment, even as the enzymes themselves are capable of altering this environment. Besides the ECM, metalloproteinases have been shown to cleave environmental receptors, such as integrins (Von Bredow et al., 1997) and cadherins (Herren et al., 1998) as well as other bioregulatory molecules including growth factors (Arribas et al., 1996; Suzuki et al., 1997; Dempsey et al., 1997) , growth factor receptors (Mullberg et al., 1995; Levi et al., 1996) and death factors (Gearing et al., 1994; Kayagaki et al., 1995) . While the relevant substrate(s) and mechanism of action are unclear, matrilysin has been shown to enhance intestinal tumor formation both in xenograft and genetically-altered animal models Wilson et al., 1997) . The in¯uence of matrilysin on intestinal tumor formation and its status as a target gene of the initiating step in intestinal tumorigenesis further emphasizes the critical role of the extracellular environment in tumorigenesis.
Materials and methods
Analysis of b-catenin and matrilysin expression in murine tumors
C57BL/6J mice (Jackson Laboratory) were treated with the carcinogen azoxymethane (AOM, Sigma Chemical Co.) beginning at 8 weeks of age. Animals were administered 6 weekly s.c. injections of 5 mg/kg of AOM and then sacri®ced approximately 29 weeks after the ®nal injection. Colons from these mice and small intestines from 120-day old C57BL/6 Min mice (Jackson Laboratory) were removed, ®xed in 4% paraformaldehyde and examined for tumors. Tumors and surrounding normal tissue were excised and embedded in paran.
For in situ hybridization, the tumors were cut into 5 mm sections and analysed for matrilysin transcripts as previously described (Wilson et al., 1995) . For immunohistochemistry, 5 mm tumor sections were subjected to antigen retrieval by microwaving in 0.1 M citrate, pH 6.0 for 4 min. The sections were incubated overnight with either a monoclonal anti-bcatenin antibody (Transduction Laboratories). Visualization was achieved using the Vectastain ABC kit (Vector Laboratories) with the chromogenic substrate 3,3'diaminobenzidine (DAB, Sigma Chemical Co.) and a counterstain of Mayer's hematoxylin (Sigma Chemical Co.).
EMSA
For comparison of matrilysin +8-Tcf (5'-AACATCAAAG-TAGCTCTGAGAA-3'), mutant matrilysin +8-Tcf (5'-AACGCCAAAGTAGCTCTGAGAA-3'), optimal Tcf-4 (5'-AGCTGGTAAGATCAAAGGG-3') and mutant Tcf-4 sites (5'-AGCTGGTAAGGCCAAAGGG-3'), complementary oligonucleotides were annealed and endlabeled with polynucleotide kinase in the presence of g- Transduction Laboratories) were preincubated with nuclear extract for 1 h on ice followed by incubation with oligonucleotide for 1 h at room temperature. Mouse bcatenin was generated and puri®ed using the IMPACT protein puri®cation system (New England Biolabs) according to manufacturer's directions. EMSA gel electrophoresis was performed according to standard methods (Ausubel et al., 1993) .
DNA constructs
A mouse matrilysin promoter fragment from 7445 ± +32 relative to the transcription start site was subcloned by PCR ampli®cation from a genomic clone (Wilson et al., 1995) and cut at an endogenous EcoRI site (7445) and a BamHI site engineered into the 3' oligonucleotide. This fragment was sequenced and con®rmed to be identical to the genomic sequence. The 2.7 kb fragment of the mouse matrilysin promoter was cloned into the SacI and BglII of the pGL2Basic promoter (Promega) by ligating the aforementioned 7445 ± +32 fragment and an upstream fragment from a contiguous genomic clone de®ned by the EcoRI site (7445) and an upstream SacI site (72.7 kb) to generate WTMMATLuc. mTcfMAT-Luc was constructed identically to WTMATluc but with the mutant 3' oligonucleotide: (5'-GGATCCC-GATTGTTCT CAG AGC TAC TTTGGCGTTTCCTGTGA-CAGGGG-3'), where bold letters indicate the point mutations. E-cadCyto and E-cadCytoD were constructed by subcloning a BamHI/SalI fragment of the canine E-cadherin cytoplasmic domain (Jou et al., 1995) or murine E-cadherin cytoplasmic domain missing the b-catenin interaction region (Jou et al., 1995) into the BamHI and XhoI sites of the CMVdriven expression vector, pCANmyc . The LEF-1 expression vector pBZ13 (Zhou et al., 1995) was the generous gift of Dr Elaine Fuchs.
Transient transfection assays
5610
5 cells were plated in each well of a six well plate and were transfected with 2.5 mg of promoter/reporter construct and 0.1 ng of SV40-Renilla Luciferase for normalizing transfection eciency using Superfect Reagent (Qiagen). Forty-eight hours after transfection, relative light units were determined with a luminometer using the Dual Luciferase Assay System (Promega). Experiments with DN89b-catenin, E-CadCyto, E-CadCytoD and LEF-1 expression vectors included 2.5 mg of the expression vector and were compared to reporter plasmid contransfected with 2.5 mg of parental pCDNA3 expression vector. Eects on general transcription, ®re¯y luciferase message or protein stability were corrected for by normalization to values from 2.5 mg of pGL2Control vector (Promega) cotransfected with 2.5 mg of the appropriate expression vector.
